

References

1. Newberry KJ, Patel K, Masarova L, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. *Blood*. 2017;130:1125-1131.
2. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. *Blood*. 2013;122:1395-1398.
3. Harrison CN, Schaap N, Vannuchi AM, et al. Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study. ASCO 2019. Abstract 7057.
4. Daver N, Kremyanskaya M, O'Connell C, et al. A phase 2 study of the safety and efficacy of INCB050465, a selective PI3K inhibitor, in combination with ruxolitinib in patients with myelofibrosis. ASH 2018. Abstract 353.
5. Oshima Y, Yamamoto Y, et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. *Cancer Res*. 2003;63:3931-3939.
6. Herbert TP, Kilhams GR, Batty IH, Proud CG. Distinct signalling pathways mediate insulin and phorbol ester-stimulated eukaryotic initiation factor 4F assembly and protein synthesis in HEK 293 cells. *Oncogene*. 2000;275:11249-11256.
7. Mascarenhas J, Komrokji RS, Cavo M, et al. Imetelstat is effective treatment for patients with intermediate-2 or high-risk myelofibrosis who have relapsed on or are refractory to Janus kinase inhibitor therapy: Results of a phase 2 randomized study of two dose levels. ASH 2018. Abstract 685.
8. Kuykendall A, Wan Y, Mascarenhas J, et al. Favorable overall survival of imetelstat-treated relapsed/refractory myelofibrosis patients compared with closely matched real world data. EHA 2019. Abstract PS1456.
9. Tse C, Shomaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. *Cancer Res*. 2008;68:3421-3248.
10. Zeuner A, Pedini F, Francesangeli F, et al. Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. *Blood*. 2009;113:1522-1525.
11. Waibel M, Solomon VS, Knight DA, et al. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. *Cell Rep*. 2013;5:1047-1059.
12. Guo J, Roberts L, Chen Z, et al. JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL. *PLoS One*. 2015;10:e0114363.
13. Lagares D, Santos A, Grasberger PE, et al. Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. *Sci Transl Med*. 2017;9(420).
14. Harrison CN, Garcia JS, Mesa RA, et al. Results from a phase 2 study of navitoclax in combination with ruxolitinib in patients with primary or secondary MF. ASH 2019. Abstract 671.
15. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor- β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. *Nat Med*. 2014;20:408-414.
16. Reblozyl [package insert]. Summit, NJ: Celgene Corporation; 2019.

17. US Food and Drug Administration. FDA approves luspatercept-aamt for anemia in adults with MDS [press release]. Available at: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-luspatercept-aamt-anemia-adults-mds>. Accessed June 5, 2020.
18. Gerds AT, Vannucchi AM, Passamonti F, et al. A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia. ASH 2019. Abstract 557.
19. Mascarenhas J, Kremyanskaya M, Hoffman R, et al. MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or “Add-on” to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. ASH 2019. Abstract 670.
20. Bottazzi B, Inforzato A, Messa M, et al. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. *J Hepatol*. 2016;64:1416-1427.
21. Verstovsek S, Mansouri T, Pilling D, et al. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. *J Exp Med*. 2016;213:1723-1740.
22. Verstovsek S, Talpaz M, Wadleigh M, et al. A randomized, double-blind phase 2 study of 2 different doses of PRM-151 in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib. EHA 2019. Abstract S828.
23. Mesa RA, Miller CB, Thyne M, et al. Differences in treatment goals and perception of symptom burden between patients and physicians with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark Survey. *Cancer*. 2017;123:449-458.